11.17
price up icon0.54%   0.06
pre-market  Pre-market:  11.17  
loading
Verve Therapeutics Inc stock is traded at $11.17, with a volume of 2.99M. It is up +0.54% in the last 24 hours and up +156.19% over the past month. Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$11.11
Open:
$11.15
24h Volume:
2.99M
Relative Volume:
0.63
Market Cap:
$569.18M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-4.3127
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
-1.85%
1M Performance:
+156.19%
6M Performance:
+93.59%
1Y Performance:
+111.55%
1-Day Range:
Value
$11.09
$11.19
1-Week Range:
Value
$11.04
$11.26
52-Week Range:
Value
$2.8647
$11.40

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
Name
Verve Therapeutics Inc
Name
Phone
(978) 501-3026
Name
Address
201 BROOKLINE AVENUE, BOSTON
Name
Employee
274
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
VERV's Discussions on Twitter

Compare VERV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VERV
Verve Therapeutics Inc
11.17 569.18M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Apr-08-24 Initiated H.C. Wainwright Buy
Apr-13-23 Initiated Canaccord Genuity Buy
Feb-01-23 Initiated Cantor Fitzgerald Neutral
Dec-15-22 Initiated Goldman Sell
Oct-06-22 Initiated Credit Suisse Neutral
Aug-25-22 Upgrade Stifel Hold → Buy
Jun-17-22 Initiated BMO Capital Markets Outperform
Feb-18-22 Initiated RBC Capital Mkts Outperform
Sep-24-21 Initiated Stifel Hold
Jul-12-21 Initiated Guggenheim Buy
Jul-12-21 Initiated JP Morgan Neutral
Jul-12-21 Initiated Jefferies Buy
Jul-12-21 Initiated William Blair Outperform
View All

Verve Therapeutics Inc Stock (VERV) Latest News

pulisher
Jun 18, 2025

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes

Jun 18, 2025
pulisher
Jun 18, 2025

This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers

Jun 18, 2025
pulisher
Jun 18, 2025

Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition news - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

Eli Lilly to acquire for Verve Therapeutics for up to $1.3B - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Why Verve Therapeutics Stock Is Skyrocketing Today - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - The Mighty 790 KFGO

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say By Reuters - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to acquire Verve Therapeutics for up to $1.3 billion By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly - Wilson Sonsini

Jun 17, 2025
pulisher
Jun 17, 2025

Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ

Jun 17, 2025
pulisher
Jun 17, 2025

These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More - Barron's

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics downgraded to Market Perform from Outperform at LifeSci - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Hold Rating on Verve Therapeutics Amid Acquisition and Development Milestones - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily

Jun 17, 2025
pulisher
Jun 17, 2025

Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN

Jun 17, 2025

Verve Therapeutics Inc Stock (VERV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Verve Therapeutics Inc Stock (VERV) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Nickerson Joan
Chief Administrative Officer
Apr 02 '25
Sale
4.15
2,777
11,525
17,420
Ashe Andrew D.
See Remarks
Apr 02 '25
Sale
4.15
2,681
11,126
348,828
Politi Jason
Chief Technical Ops. Off.
Apr 02 '25
Sale
4.15
3,235
13,425
14,226
Dorval Allison
Chief Financial Officer
Apr 02 '25
Sale
4.15
3,350
13,903
13,280
Lister Troy
Chief Scientific Officer
Apr 02 '25
Sale
4.15
2,189
9,084
6,952
Dorval Allison
Chief Financial Officer
Dec 02 '24
Sale
5.64
555
3,130
5,380
Kathiresan Sekar
Chief Executive Officer
Jun 28 '24
Option Exercise
2.87
30,000
86,100
351,128
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Cap:     |  Volume (24h):